Evidence map›Paper›PMID 40718607›Full record

ArticleEuroasian journal of hepato-gastroenterology

Evaluating Clinical Outcomes of Adjunct Rifaximin Therapy in Patients with Overt Hepatic Encephalopathy: A Prospective Randomized Study.

Hosam Alazazzi, Ahmed T Algahiny, Zain Sharif, Niloy Sil, Yasir A Zaidi, Farhad R Mashori, Bawan Ali, Aemon F Jaffery, Omar He Abouelella, Udoy Sil and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hosam AlazazziDepartment of Internal Medicine, School of Medicine, Royal College of Surgeons in Ireland - Bahrain, Busaiteen, Bahrain.
Ahmed T AlgahinyDepartment of Internal Medicine, School of Medicine, Royal College of Surgeons in Ireland - Bahrain, Busaiteen, Bahrain.
Zain SharifDepartment of Gastroenterology and Hepatology, Nishtar Hospital, Multan, Pakistan.
Niloy SilDepartment of Internal Medicine, Wrightington, Wigan and Leigh National Health Service Foundation Trust, Wigan, United Kingdom.
Yasir A ZaidiDepartment of Gastroenterology and Hepatology, Nishtar Hospital, Multan, Pakistan.
Farhad R MashoriDepartment of Gastroenterology and Hepatology, Nishtar Hospital, Multan, Pakistan.
Bawan AliDepartment of Internal Medicine, Wrightington, Wigan and Leigh National Health Service Foundation Trust, Wigan, United Kingdom.
Aemon F JafferyDepartment of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan.
Omar He AbouelellaDepartment of Internal Medicine, New Giza University, Giza, Egypt.
Udoy SilDepartment of Internal Medicine, Wrightington, Wigan and Leigh National Health Service Foundation Trust, Wigan, United Kingdom.
Muneeb UllahDepartment of General Surgery, Maroof International Hospital, Islamabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study was conducted to assess the therapeutic benefit of using rifaximin in combination with lactulose vs lactulose alone in the management of overt hepatic encephalopathy (OHE) within a tertiary care setting. Methods: A randomized controlled trial was conducted with 132 adult patients diagnosed with decompensated liver cirrhosis and presenting with OHE of West Haven Criteria grade II or higher. Participants were randomly allocated to receive either combination therapy (CT), comprising rifaximin and lactulose, or lactulose monotherapy (LM). Clinical outcomes were monitored over a 10-day period or until symptom resolution. The key outcome measure was symptom resolution in OHE, defined by reduction in grade and resolution of neurocognitive deficits. Results: Clinical improvement was achieved in 80.3% ( Conclusion: The addition of rifaximin to standard lactulose therapy significantly improved clinical outcomes in patients with OHE, particularly among male patients and those in older age-groups, reinforcing its role as a preferred treatment strategy for OHE. How to cite this article: Alazazzi H, Algahiny AT, Sharif Z,

Indexed as

Decompensated chronic liver diseaseLactulose monotherapyOvert hepatic encephalopathyRifaximin–lactulose therapy

Identifiers

PMID40718607
PMCPMC12288574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.